Outsourcing

On Nov. 17, 2010, Novartis (Basel) disclosed its long-term business strategy, which emphasizes diversification in what the company described as high-growth healthcare segments.

Genzyme Sells Business Unit to Sekisui Chemical; Ablexis Names VP of Research; and More.

During the 20 months before the crisis of contaminated heparin in early 2008, the US Food and Drug Administration did not inspect any Chinese heparin firms, according to a US Government Accountability Office, (GAO) report.

Roche Details Restructuring Plan; Sigma-Aldrich Names Successors after CEO's Death; and More.

The US Food and Drug Administration's Puerto Rico district office "may be having difficulty exercising oversight on the numerous pharmaceutical manufacturing facilities on the island," according to Rep. Edolphus Towns (D-NY), chair of the US House of Representatives Committee on Oversight and Government Reform.

Eli Lilly Acquires Avid Radiopharmaceuticals; EMA Recruiting New Director; and More

The growth in pharmaceutical outsourcing is creating a more complex and risky supply-chain environment, according to a report issued last week.

sanofi acquires BMP Sunstone; DCAT Names President; and More.

From fiscal year 2007 to 2009, the US Food and Drug Administration increased the number of foreign drug inspections it conducted, but the agency still conducted fewer foreign inspections than domestic inspections each year, according to a recent report by the US Government Accountability Office (GAO).

IP rights and levels of innovation have opened a bit of controversy regarding decisions being made by Indian courts and legislators.

As technology advances, industry's needs are growing.

Scientists and practitioners must work together for the overall good of the patient.

A new center may provide evidence for improving care, but could discourage coverage of treatments.

Post recession and beyond, which contract service providers will still be standing?

Stuart Needleman, president of active-ingredient development and manufacturing at Aptuit, discusses industry trends and challenges.

PPD and Bend Research Form Collaboration; Ricerca Makes Senior Appointment; And More.

Pfizer Forms Pact with Biocon; Baxter Makes Appointments; And More.

During Oct. 5-12, 2010, more than 40 countries cooperated in an international week of action to combat the online sale of counterfeit and illegal drugs and to raise awareness of their associated health risks.

sanofi to Cut 25% of US Workforce; AMRI Names VP of Chemical Development; And More.

Company and People Notes: Novartis Settles with US Attorney's Office; Hospira Names VP, And More.

The reopened debate over embryonic-stem-cell research could stifle many other scientific pursuits.

Public-private R&D partnerships are on the rise across Europe, but national goals and academia-industry competition could prevent their success at the European level.

Global pharmaceutical companies could have a problem getting rid of redundant facilities.

In light of compendial changes, representatives of the US Pharmacopeia and an industry consortium provide perspectives on cap and ferrule labels.

President Obama and HHS eye innovation and countermeasures to protect public health.

The development of quality agreements has long been recognised as a critical activity to ensure a product's quality meets regulatory requirements.

The FDA has issued a final rule that clarifies what safety information must be reported during clinical trials of investigational drugs and biologics.

Novartis Sells US Enablex Rights; Ricerca Names Chemistry Director; And More.

DSM and PolyTherics in Development Deal; Kite Pharma Appoints President and CEO, And More.

Genzyme Sells Genetics Business; Bausch and Lomb Names Vice-President; and More.